InFocus Capital Partners
12
14M
9
1
0.25
- Areas of investment
Summary
Besides them, we counted 2 critical employees of this fund in our database.
The important activity for fund was in 2019. The fund is generally included in 2-6 deals every year. Considering the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. The usual things for fund are deals in the range of 5 - 10 millions dollars.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the InFocus Capital Partners, startups are often financed by National Institutes of Health, ExSight Ventures, Wolfpack Investor Network. The meaningful sponsors for the fund in investment in the same round are Hatteras Venture Partners, ExSight Ventures, Aju IB Investment. In the next rounds fund is usually obtained by Hatteras Venture Partners, ExSight Ventures, Correlation Ventures.
Among the most popular portfolio startups of the fund, we may highlight Alievio, ONL Therapeutics. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Medical Device, Medical. The fund has no exact preference in some founders of portfolio startups.
Investments analytics
Analytics
- Total investments
- 12
- Lead investments
- 1
- Follow on index
- 0.25
- Investments by industry
- Therapeutics (8)
- Health Care (7)
- Biotechnology (5)
- Medical (4)
- Pharmaceutical (3) Show 9 more
- Investments by region
-
- United States (10)
- United Kingdom (2)
- Peak activity year
- 2020
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Group Appearance index
- 0.83
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Galimedix Therapeutics | 01 Jan 2020 | Pharmaceutical, Therapeutics | Seed | United States, Maryland, Kensington | |
| ONL Therapeutics | 22 Dec 2020 | Biotechnology, Pharmaceutical, Therapeutics | Early Stage Venture | 46M | United States, Ann Arbor, Michigan |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.